Cellular Immunotherapy LTFU

Fred Hutch's Cellular Immunotherapy Long-Term Follow-Up (LTFU) program provides monitoring and care for patients following Cellular Immunotherapy. Our services are provided through the Hutch and the Seattle Cancer Care Alliance (SCCA).

Fred Hutch clinicians and researchers work in partnership with patients’ personal doctors and other healthcare providers to resolve medical problems that may develop after cellular immunotherapy and gather information for research. This information is used to better understand the potential long-term complications after cellular immunotherapy and to develop strategies for preventing and treating the long-term effects of cellular immunotherapy.

Please Read Below Before Accessing the Physician Guidelines

These guidelines and the information they contain are copyrighted material of Fred Hutch and Seattle Cancer Care Alliance ("FHCRC / SCCA"), all rights reserved. They are intended solely for the use of referring physicians who are involved in the care of patients who have had cellular immunotherapy at FHCRC / SCCA. They may not be used for any other purpose, and FHCRC / SCCA disclaims all liability for the use of these guidelines except as expressly permitted by FHCRC / SCCA. No portion of these guidelines may be copied, displayed for redistribution to third parties for commercial purposes or for any non-permitted use without the prior written permission of FHCRC / SCCA.


These guidelines have been developed based on the available literature and the experience of physicians and patients at FHCRC / SCCA. These guidelines are periodically updated and therefore should be re-confirmed before use. Recommendations in these guidelines must be implemented in a medically reasonable way that is based upon the independent medical judgment of the treating physician and which accounts for the specific situation of the individual patient. Recommendations for patients who are enrolled in specific protocols may differ from the recommendations in these guidelines and will be communicated separately. Questions concerning the recommendations in these guidelines or their application to particular patients should be directed to the Cellular Immunotherapy LTFU office (phone: 206-667-5811; email: imtxltfu@fredhutch.org).”
 

Guidelines and Information

Immunotherapy (IMTX): Vaccination after B cell-targeted CAR-T cell therapy for Adult and Pediatric Immunotherapy Patients

+

Published Papers

Late Effects after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

+

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen receptor T Cell Therapy

+

Contact Us

Patient and Physician Contact

Patients and their local providers are welcome to contact our team.